Determinação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicose
Autor(a) principal: | |
---|---|
Data de Publicação: | 2008 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFPA |
Texto Completo: | http://www.repositorio.ufpa.br:8080/jspui/handle/2011/1865 |
Resumo: | Chromoblastomycosis is a subcutaneous mycosis caused by deployment transcutaneous of several species of dematiaceous fungi, that is, melanized fungi. Considering the incidence of this disease in the state of Pará and the resulting morbidity of patients affected, with economic and social repercussions, it was made to the optimization of therapeutic schemes adopted, to the best knowledge of the relation dose x response. The itraconazole is one of the few drugs available for treatment, which has marked variability kinetic intra and inter individual, which compromises the establishment of the relation dose and response, as well as tissue and plasma concentrations achieved. In this sense, this work aimed at validation of analytical methodology by High Performance Liquid Chromatography and subsequent determination of itraconazole in samples of plasma and tissue in 20 patients with chromoblastomycosis, assisted in the laboratory of dermatoimmunology Dr. Marcello Candia, Marituba, Pará, who used the drug in doses of 200mg/day and 400mg/day. The technique employed was validated and proved adequate results in accordance with applicable law. Concentrations of plasma and tissue of itraconazole in the dose of 200mg/day were 121.3 87.9 ng/mL and 5.36 5.9 μg/g. The average plasma concentration of itraconazole in patients using 400mg/day was 290 234 ng/mL, and the plasma and tissue mean concentrations of itraconazole in patients who showed no clinical favourable, at doses of 200mg, making it necessary to increase to 400mg were 217 216 and 304 173 ng/mL; 14.87 12.94 e 21.80 6.62 μg/g. The average of relation between tissue and plasma concentrations in patients who had positive developments in clinical in the doses of 200mg/day was 44.29 67.12 and those that did not show positive developments in clinical in the doses of 200mg/day, making necessary to increase to 400mg/day were 68.52 59.90 and 71.71 38.26 respectively. |
id |
UFPA_60e1bdfec8b34faa3c9aafcb957c3bab |
---|---|
oai_identifier_str |
oai:repositorio.ufpa.br:2011/1865 |
network_acronym_str |
UFPA |
network_name_str |
Repositório Institucional da UFPA |
repository_id_str |
2123 |
spelling |
2011-03-23T21:19:38Z2011-03-23T21:19:38Z2008-09-01GRISÓLIA, Daniella Paternostro de Araújo. Determinação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicose. 2008. 101 f. Dissertação (Mestrado) - Universidade Federal do Pará, Instituto de Ciências da Saúde, Belém, 2008. Programa de Pós-Graduação em Ciências Farmacêuticas.http://www.repositorio.ufpa.br:8080/jspui/handle/2011/1865Chromoblastomycosis is a subcutaneous mycosis caused by deployment transcutaneous of several species of dematiaceous fungi, that is, melanized fungi. Considering the incidence of this disease in the state of Pará and the resulting morbidity of patients affected, with economic and social repercussions, it was made to the optimization of therapeutic schemes adopted, to the best knowledge of the relation dose x response. The itraconazole is one of the few drugs available for treatment, which has marked variability kinetic intra and inter individual, which compromises the establishment of the relation dose and response, as well as tissue and plasma concentrations achieved. In this sense, this work aimed at validation of analytical methodology by High Performance Liquid Chromatography and subsequent determination of itraconazole in samples of plasma and tissue in 20 patients with chromoblastomycosis, assisted in the laboratory of dermatoimmunology Dr. Marcello Candia, Marituba, Pará, who used the drug in doses of 200mg/day and 400mg/day. The technique employed was validated and proved adequate results in accordance with applicable law. Concentrations of plasma and tissue of itraconazole in the dose of 200mg/day were 121.3 87.9 ng/mL and 5.36 5.9 μg/g. The average plasma concentration of itraconazole in patients using 400mg/day was 290 234 ng/mL, and the plasma and tissue mean concentrations of itraconazole in patients who showed no clinical favourable, at doses of 200mg, making it necessary to increase to 400mg were 217 216 and 304 173 ng/mL; 14.87 12.94 e 21.80 6.62 μg/g. The average of relation between tissue and plasma concentrations in patients who had positive developments in clinical in the doses of 200mg/day was 44.29 67.12 and those that did not show positive developments in clinical in the doses of 200mg/day, making necessary to increase to 400mg/day were 68.52 59.90 and 71.71 38.26 respectively.Cromoblastomicose é micose subcutânea causada pela implantação transcutânea de diversas espécies de fungos demáceos, isto é, fungos melanizados. Considerando a incidência desta doença no estado do Pará e a conseqüente morbidade dos pacientes afetados, com repercussões sociais e econômicas, fez-se necessário a otimização dos esquemas terapêuticos adotados, objetivando o melhor conhecimento da relação dose x resposta. O itraconazol é um dos poucos fármacos disponíveis para o tratamento, que apresenta marcada variabilidade cinética intra e inter individual, que compromete o estabelecimento da relação dose e resposta, bem como as concentrações plasmáticas e teciduais alcançadas. Neste sentido, este trabalho objetivou a validação da metodologia analítica por Cromatografia Líquida de Alta Eficiência e posterior determinação de itraconazol em amostras de plasma e tecido em 20 pacientes com cromoblastomicose, atendidos no laboratório de Dermato-Imunologia Dr. Marcello Candia, Marituba, Pará, que utilizaram o medicamento nas doses de 200mg/dia e 400mg/dia. A técnica validada demonstrou resultados adequados de acordo com a legislação vigente. As concentrações plasmáticas e teciduais de itraconazol na dose de 200mg/dia foram 121.3 87.9 ng/mL e 5.36 5.9 μg/g a concentração plasmática média de itraconazol em pacientes usando 400mg/dia foi de 290 234 ng/mL, e as concentrações plasmáticas e teciduais médias de itraconazol nos pacientes que não apresentaram evolução clínica favorável, nas doses de 200mg, tornando-se necessário o aumento para 400mg foram 217 216 e 304 173 ng/mL ; 14.87 12.94 e 21.80 6.62 μg/g. A média das relações entre as concentrações teciduais e plasmáticas nos pacientes que apresentaram evolução clínica favorável nas doses de 200mg/dia foi 44.29 67.12 e as que não apresentaram evolução clínica favorável nas doses de 200mg/dia, sendo necessário o aumento para 400mg/dia foram 68.52 59.90 ; 71.71 38.26 respectivamente.porUniversidade Federal do ParáPrograma de Pós-Graduação em Ciências FarmacêuticasUFPABrasilInstituto de Ciências da SaúdeCNPQ::CIENCIAS DA SAUDE::FARMACIA::ANALISE E CONTROLE E MEDICAMENTOSPará - EstadoItraconazolFarmacologiaCromoblastomicoseCromatografia líquida de alta eficiênciaMicoseAmazônia brasileiraDeterminação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicoseDetermination of the plasmáticas and teciduais concentrations of itraconazol in patients with cromoblastomicoseinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisVIEIRA, José Luiz Fernandeshttp://lattes.cnpq.br/2739079559531098http://lattes.cnpq.br/5401893631545404GRISÓLIA, Daniella Paternostro de Araújoinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFPAinstname:Universidade Federal do Pará (UFPA)instacron:UFPAORIGINALDissertacao_DeterminacaoConcentracoesPlasmaticas.pdfDissertacao_DeterminacaoConcentracoesPlasmaticas.pdfapplication/pdf1179081http://repositorio.ufpa.br/oai/bitstream/2011/1865/1/Dissertacao_DeterminacaoConcentracoesPlasmaticas.pdf85b7fd334cc4e6fe380f14428a831f55MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-823930http://repositorio.ufpa.br/oai/bitstream/2011/1865/2/license_rdf6b71892b27c4389434057b8b0e86b43eMD52license_textlicense_texttext/html; charset=utf-823738http://repositorio.ufpa.br/oai/bitstream/2011/1865/3/license_text1a64b812a61c51c296c1ad647d0096a6MD53license_urllicense_urltext/plain; charset=utf-852http://repositorio.ufpa.br/oai/bitstream/2011/1865/4/license_url3d480ae6c91e310daba2020f8787d6f9MD54TEXTDissertacao_DeterminacaoConcentracoesPlasmaticas.pdf.txtDissertacao_DeterminacaoConcentracoesPlasmaticas.pdf.txtExtracted texttext/plain118323http://repositorio.ufpa.br/oai/bitstream/2011/1865/5/Dissertacao_DeterminacaoConcentracoesPlasmaticas.pdf.txtb37fe07d46f434930f12662caf054440MD552011/18652019-05-23 10:25:47.11oai:repositorio.ufpa.br:2011/1865Repositório InstitucionalPUBhttp://repositorio.ufpa.br/oai/requestriufpabc@ufpa.bropendoar:21232019-05-23T13:25:47Repositório Institucional da UFPA - Universidade Federal do Pará (UFPA)false |
dc.title.none.fl_str_mv |
Determinação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicose |
dc.title.alternative.none.fl_str_mv |
Determination of the plasmáticas and teciduais concentrations of itraconazol in patients with cromoblastomicose |
title |
Determinação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicose |
spellingShingle |
Determinação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicose GRISÓLIA, Daniella Paternostro de Araújo CNPQ::CIENCIAS DA SAUDE::FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS Pará - Estado Itraconazol Farmacologia Cromoblastomicose Cromatografia líquida de alta eficiência Micose Amazônia brasileira |
title_short |
Determinação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicose |
title_full |
Determinação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicose |
title_fullStr |
Determinação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicose |
title_full_unstemmed |
Determinação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicose |
title_sort |
Determinação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicose |
author |
GRISÓLIA, Daniella Paternostro de Araújo |
author_facet |
GRISÓLIA, Daniella Paternostro de Araújo |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
VIEIRA, José Luiz Fernandes |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/2739079559531098 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/5401893631545404 |
dc.contributor.author.fl_str_mv |
GRISÓLIA, Daniella Paternostro de Araújo |
contributor_str_mv |
VIEIRA, José Luiz Fernandes |
dc.subject.cnpq.fl_str_mv |
CNPQ::CIENCIAS DA SAUDE::FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS |
topic |
CNPQ::CIENCIAS DA SAUDE::FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS Pará - Estado Itraconazol Farmacologia Cromoblastomicose Cromatografia líquida de alta eficiência Micose Amazônia brasileira |
dc.subject.por.fl_str_mv |
Pará - Estado Itraconazol Farmacologia Cromoblastomicose Cromatografia líquida de alta eficiência Micose Amazônia brasileira |
description |
Chromoblastomycosis is a subcutaneous mycosis caused by deployment transcutaneous of several species of dematiaceous fungi, that is, melanized fungi. Considering the incidence of this disease in the state of Pará and the resulting morbidity of patients affected, with economic and social repercussions, it was made to the optimization of therapeutic schemes adopted, to the best knowledge of the relation dose x response. The itraconazole is one of the few drugs available for treatment, which has marked variability kinetic intra and inter individual, which compromises the establishment of the relation dose and response, as well as tissue and plasma concentrations achieved. In this sense, this work aimed at validation of analytical methodology by High Performance Liquid Chromatography and subsequent determination of itraconazole in samples of plasma and tissue in 20 patients with chromoblastomycosis, assisted in the laboratory of dermatoimmunology Dr. Marcello Candia, Marituba, Pará, who used the drug in doses of 200mg/day and 400mg/day. The technique employed was validated and proved adequate results in accordance with applicable law. Concentrations of plasma and tissue of itraconazole in the dose of 200mg/day were 121.3 87.9 ng/mL and 5.36 5.9 μg/g. The average plasma concentration of itraconazole in patients using 400mg/day was 290 234 ng/mL, and the plasma and tissue mean concentrations of itraconazole in patients who showed no clinical favourable, at doses of 200mg, making it necessary to increase to 400mg were 217 216 and 304 173 ng/mL; 14.87 12.94 e 21.80 6.62 μg/g. The average of relation between tissue and plasma concentrations in patients who had positive developments in clinical in the doses of 200mg/day was 44.29 67.12 and those that did not show positive developments in clinical in the doses of 200mg/day, making necessary to increase to 400mg/day were 68.52 59.90 and 71.71 38.26 respectively. |
publishDate |
2008 |
dc.date.issued.fl_str_mv |
2008-09-01 |
dc.date.accessioned.fl_str_mv |
2011-03-23T21:19:38Z |
dc.date.available.fl_str_mv |
2011-03-23T21:19:38Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
GRISÓLIA, Daniella Paternostro de Araújo. Determinação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicose. 2008. 101 f. Dissertação (Mestrado) - Universidade Federal do Pará, Instituto de Ciências da Saúde, Belém, 2008. Programa de Pós-Graduação em Ciências Farmacêuticas. |
dc.identifier.uri.fl_str_mv |
http://www.repositorio.ufpa.br:8080/jspui/handle/2011/1865 |
identifier_str_mv |
GRISÓLIA, Daniella Paternostro de Araújo. Determinação das concentrações plasmáticas e teciduais de itraconazol em pacientes com cromoblastomicose. 2008. 101 f. Dissertação (Mestrado) - Universidade Federal do Pará, Instituto de Ciências da Saúde, Belém, 2008. Programa de Pós-Graduação em Ciências Farmacêuticas. |
url |
http://www.repositorio.ufpa.br:8080/jspui/handle/2011/1865 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Universidade Federal do Pará |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Ciências Farmacêuticas |
dc.publisher.initials.fl_str_mv |
UFPA |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
Instituto de Ciências da Saúde |
publisher.none.fl_str_mv |
Universidade Federal do Pará |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFPA instname:Universidade Federal do Pará (UFPA) instacron:UFPA |
instname_str |
Universidade Federal do Pará (UFPA) |
instacron_str |
UFPA |
institution |
UFPA |
reponame_str |
Repositório Institucional da UFPA |
collection |
Repositório Institucional da UFPA |
bitstream.url.fl_str_mv |
http://repositorio.ufpa.br/oai/bitstream/2011/1865/1/Dissertacao_DeterminacaoConcentracoesPlasmaticas.pdf http://repositorio.ufpa.br/oai/bitstream/2011/1865/2/license_rdf http://repositorio.ufpa.br/oai/bitstream/2011/1865/3/license_text http://repositorio.ufpa.br/oai/bitstream/2011/1865/4/license_url http://repositorio.ufpa.br/oai/bitstream/2011/1865/5/Dissertacao_DeterminacaoConcentracoesPlasmaticas.pdf.txt |
bitstream.checksum.fl_str_mv |
85b7fd334cc4e6fe380f14428a831f55 6b71892b27c4389434057b8b0e86b43e 1a64b812a61c51c296c1ad647d0096a6 3d480ae6c91e310daba2020f8787d6f9 b37fe07d46f434930f12662caf054440 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFPA - Universidade Federal do Pará (UFPA) |
repository.mail.fl_str_mv |
riufpabc@ufpa.br |
_version_ |
1801771964594913280 |